Pharma companies likely to post 15% profit growth in Q3 FY'14

Tags: News
Pharmaceutical companies are expected to post core profit growth of over 15 per cent, year-on-year, for the quarter ended December 2013.

"We expect core profit growth of over 15 per cent y-o-y across the pharmaceutical sector in Q3 FY'14. The US launches and currency benefit to be the key growth drivers," Kotak Institutional Equities said in its report.

While the domestic growth stays subdued, the US launches remain strong, it said. It expects the US generic launches to be the key growth driver, offsetting weak growth in India.

The improving US product mix and currency remain key margin drivers for Indian generics, according to the report.

"The currency benefit is likely to sustain. In the current quarter, The Indian rupee has appreciated by 1 per cent sequentially on a quarter-end basis. Hence, we expect marginal impact due to translation impact of net balance-sheet items and MTM losses on foreign currency hedges," said Kotak Equities research analyst Krishna Prasad.

Among the leading pharma players, Sun Pharma and Dr Reddy's will lead the sector, while Lupin US generics growth is expected to remain strong, it said, adding that Kotak expects a stable growth for Glenmark and remains conservative on recovery in Cipla and Cadila in the third quarter of the 2013-14 fiscal (Q3 FY'14), the report said.

"We expect core profit growth of over 15 per cent yoy across the sector except Cipla. Sun Pharma and Dr Reddy's will lead the pack--with 45 per cent and 33 per cent yoy net profit growth, respectively. In both cases, we expect US generics to be the primary growth driver along with currency," Prasad said.


  • All the debates are glossing over the key question if children are eating healthy food

    For some time now, we have been strapped in noodle debates. First Maggie noodles and now our own swadeshi noodles that Baba Ramdev is making.


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Amita Sharma

Smart cities for the smart citizens

The 21st century has been spoken of as the urban ...

Zehra Naqvi

Baby and you

Every person who’s had a chance to be a parent ...

Bubbles Sabharwal

Women of the world, unite for a change

Last week I attended the Women in the World forum ...


William D. Green

Chairman & CEO, Accenture